- Home
- MPC vs RVPHW Comparison
MPC vs RVPHW Comparison
Compare MPC & RVPHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPC
- RVPHW
- Stock Information
- Founded
- MPC 1887
- RVPHW 2018
- Country
- MPC United States
- RVPHW United States
- Employees
- MPC N/A
- RVPHW 14
- Industry
- MPC Integrated oil Companies
- RVPHW Biotechnology: Pharmaceutical Preparations
- Sector
- MPC Energy
- RVPHW Health Care
- Exchange
- MPC Nasdaq
- RVPHW Nasdaq
- Market Cap
- MPC N/A
- RVPHW N/A
- IPO Year
- MPC 2011
- RVPHW N/A
- Fundamental
- Price
- MPC $149.97
- RVPHW $0.06
- Analyst Decision
- MPC Buy
- RVPHW
- Analyst Count
- MPC 13
- RVPHW 0
- Target Price
- MPC $172.08
- RVPHW N/A
- AVG Volume (30 Days)
- MPC 2.5M
- RVPHW 22.4K
- Earning Date
- MPC 05-06-2025
- RVPHW 03-14-2025
- Dividend Yield
- MPC 2.43%
- RVPHW N/A
- EPS Growth
- MPC N/A
- RVPHW N/A
- EPS
- MPC 7.39
- RVPHW N/A
- Revenue
- MPC $137,969,000,000.00
- RVPHW N/A
- Revenue This Year
- MPC N/A
- RVPHW N/A
- Revenue Next Year
- MPC N/A
- RVPHW N/A
- P/E Ratio
- MPC $20.30
- RVPHW N/A
- Revenue Growth
- MPC N/A
- RVPHW N/A
- 52 Week Low
- MPC $115.10
- RVPHW $0.13
- 52 Week High
- MPC $184.72
- RVPHW $0.15
- Technical
- Relative Strength Index (RSI)
- MPC 67.64
- RVPHW N/A
- Support Level
- MPC $133.00
- RVPHW N/A
- Resistance Level
- MPC $146.35
- RVPHW N/A
- Average True Range (ATR)
- MPC 4.00
- RVPHW 0.00
- MACD
- MPC 2.17
- RVPHW 0.00
- Stochastic Oscillator
- MPC 93.59
- RVPHW 0.00
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.